Peer-influenced content. Sources you trust. No registration required. This is HCN.
Gastroenterology Advisor
Continuous mirikizumab treatment demonstrated durable efficacy across multiple outcome measures for over three years, with 70.1% of week-52 remitters maintaining clinical remission at week 152 and comparable quality of life improvements in both biologic-naïve and biologic-failure patients.
Gastroenterology May 1st 2025
Consultant360
Combined omalizumab-OIT therapy demonstrated an impressive 50-percentage-point advantage over placebo in food challenge success rates for children with multiple food allergies.
Allergy & Immunology January 8th 2025
Oncology News Central (ONC)
Subcutaneous administration of amivantamab demonstrated noninferiority to IV delivery while potentially offering enhanced patient convenience and reduced healthcare system burden.
Oncology, Medical January 7th 2025
Rheumatology Advisor
Understanding the role of antidrug antibodies in RA treatment can significantly impact patient management. Stay updated on how these antibodies correlate with bDMARD effectiveness to optimize your treatment plans.
Rheumatology October 4th 2023
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS